Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 14,120Xls

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251217824138/en/Vistagen-Announces-Topline-Results-from-PALISADE-3-Phase-3-Public-Speaking-Challenge-Study-of-Fasedienol-for-the-Acute-Treatment-of-Social-Anxiety-Disorder

BUSINESSWIRE
18 Dec 2025

https://www.businesswire.com/news/home/20251103479407/en/Vistagen-Completes-PALISADE-3-Phase-3-Public-Speaking-Challenge-Study-for-the-Acute-Treatment-of-Social-Anxiety-Disorder

BUSINESSWIRE
03 Nov 2025

https://www.businesswire.com/news/home/20250602738861/en/Vistagen-on-Track-to-Deliver-Topline-Data-From-Fasedienol-PALISADE-3-Phase-3-Trial-for-Acute-Treatment-of-Social-Anxiety-Disorder-in-the-Fourth-Quarter-of-This-Year

BUSINESSWIRE
02 Jun 2025

https://www.businesswire.com/news/home/20240923438804/en

BUSINESSWIRE
23 Sep 2024

https://www.businesswire.com/news/home/20240401402849/en

BUSINESSWIRE
01 Apr 2024

https://www.prnewswire.com/news-releases/affamed-therapeutics-announces-partner-vistagen-reports-positive-top-line-results-from-phase-3-palisade-2-trial-of-fasedienol-ph94b-nasal-spray-in-social-anxiety-disorder-301897671.html

PR NEWSWIRE
10 Aug 2023